Company Number: 12841074

Analysis Date: 2025-07-20 12:04 UTC

1. Risk Rating: LOW
   The company exhibits strong solvency and liquidity metrics, with net assets of £1.78 million and substantial cash holdings (£1.44 million) at the 2024 year end. The absence of overdue filings and the single director’s active involvement further support operational stability.

2. Key Concerns:

• Concentration risk due to sole director and 100% ownership by Dr. Susan Cleator, which may pose governance and succession risks.
• Significant increase in investments (£199k addition in 2024) in an unlisted entity that is carried at cost with no impairment provision noted; this could potentially affect asset realizability.
• Director loans to the sole director totaling £76,749, while interest-bearing and repayable on demand, represent a related-party transaction requiring monitoring for potential liquidity impact.

3. Positive Indicators:

• Consistent growth in net assets and net current assets over recent years, indicating financial strengthening.
• Strong liquidity position demonstrated by cash representing nearly 80% of current assets and a current ratio well above 1, suggesting ability to meet short-term obligations comfortably.
• Timely compliance with statutory filing deadlines and no indications of regulatory or governance issues.

4. Due Diligence Notes:

• Review the nature and risks of the unlisted investment to assess impairment risk and valuation reliability.
• Confirm the terms and repayment status of the director loan to ensure no hidden liquidity constraints.
• Assess operational dependence on the sole director and any business continuity plans in place.
• Verify absence of contingent liabilities or off-balance-sheet risks not disclosed in the accounts.